Pharmaceutical

Ibutamoren mesylate by Lumos Pharma for Growth Hormone Deficiency: Likelihood of Approval

Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency.

May 5, 2024 - 00:00
Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency.
Read the original article

Tags:

Previous Article

ImmunityBio partners with Serum Institute for BCG vaccines

Next Article

GIST-MIT CSAIL researchers develop a biomechanical dataset for badminton perform...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Market cap downturn hits over half of top 20 biopharmaceutical companies in Q1 2023

Market cap downturn hits over half of top 20 biopharmac...

May 16, 2023

Magazine: UK’s new Netflix-style funding model for antibiotics goes live

Magazine: UK’s new Netflix-style funding model for anti...

Jun 26, 2024

Niacin has long been a public health darling. But an excess could be bad for the heart, study suggests

Niacin has long been a public health darling. But an ex...

Feb 19, 2024